New microRNA biomarkers for drug-induced steatosis and their potential to predict the contribution of drugs to non-alcoholic fatty liver disease
NAGIOS: RODERIC FUNCIONANDO

New microRNA biomarkers for drug-induced steatosis and their potential to predict the contribution of drugs to non-alcoholic fatty liver disease

DSpace Repository

New microRNA biomarkers for drug-induced steatosis and their potential to predict the contribution of drugs to non-alcoholic fatty liver disease

Show simple item record

dc.contributor.author López-Riera, Mireia
dc.contributor.author Conde, Isabel
dc.contributor.author Tolosa, Laia
dc.contributor.author Zaragoza, Angela
dc.contributor.author Castell Ripoll, José Vicente
dc.contributor.author Gómez-Lechón, María J.
dc.contributor.author Jover Atienza, Ramiro
dc.date.accessioned 2018-04-19T14:20:25Z
dc.date.available 2018-04-19T14:20:25Z
dc.date.issued 2017
dc.identifier.uri http://hdl.handle.net/10550/65807
dc.description.abstract Background and Aims: Drug-induced steatosis is a major reason for drug failure in clinical trials and post-marketing withdrawal; and therefore, predictive biomarkers are essential. These could be particularly relevant in non-alcoholic fatty liver disease (NAFLD), where most patients show features of the metabolic syndrome and are prescribed with combined chronic therapies, which can contribute to fatty liver. However, specific biomarkers to assess the contribution of drugs to NAFLD are lacking. We aimed to find microRNAs (miRNAs) responsive to steatotic drugs and to investigate if they could become circulating biomarkers for drug-induced steatosis. Methods: Human HepG2 cells were treated with drugs and changes in miRNA levels were measured by microarray and qRT-PCR. Drug-induced fat accumulation in HepG2 was analyzed by high-content screening and enzymatic methods. miRNA biomarkers were also analyzed in the sera of 44 biopsy-proven NAFLD patients and in 10 controls. Results: We found a set of 10 miRNAs [miR-22-5p, -3929, -24-2-5p, -663a, -29a-3p, -21 (5p and 3p), -27a-5p, -1260 and -202-3p] that were induced in human HepG2 cells and secreted to the culture medium upon incubation with model steatotic drugs (valproate, doxycycline, cyclosporin A and tamoxifen). Moreover, cell exposure to 17 common drugs for NAFLD patients showed that some of them (e.g., irbesartan, fenofibrate, and omeprazole) also induced these miRNAs and increased intracellular triglycerides, particularly in combinations. Finally, we found that most of these miRNAs (60%) were detected in human serum, and that NAFLD patients under fibrates showed both induction of these miRNAs and a more severe steatosis grade. Conclusion: Steatotic drugs induce a common set of hepatic miRNAs that could be used in drug screening during preclinical development. Moreover, most of these miRNAs are serum circulating biomarkers that could become useful in the diagnosis of iatrogenic steatosis.
dc.language.iso eng
dc.relation.ispartof Frontiers In Pharmacology, 2017, vol. 8, num. 3, p. 1-12
dc.rights.uri info:eu-repo/semantics/openAccess
dc.source López-Riera, Mireia Conde, Isabel Tolosa, Laia Zaragoza, Angela Castell Ripoll, José Vicente Gómez-Lechón, María J. Jover Atienza, Ramiro 2017 New microRNA biomarkers for drug-induced steatosis and their potential to predict the contribution of drugs to non-alcoholic fatty liver disease Frontiers In Pharmacology 8 3 1 12
dc.subject Patologia
dc.subject Drogues
dc.subject Farmacologia
dc.title New microRNA biomarkers for drug-induced steatosis and their potential to predict the contribution of drugs to non-alcoholic fatty liver disease
dc.type info:eu-repo/semantics/article
dc.date.updated 2018-04-19T14:20:25Z
dc.identifier.doi https://doi.org/10.3389/fphar.2017.00003
dc.identifier.idgrec 125159

View       (4.460Mb)

This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search

Browse

Statistics